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BACKGROUND: Classical Hodgkin’s lymphoma (cHL), although a malignant disease, has many features in common with an inflammatory
condition. The aim of this study was to establish the molecular characteristics of the two most common cHL subtypes, nodular
sclerosis (NS) and mixed cellularity (MC), based on molecular profiling and immunohistochemistry, with special reference to the
inflammatory microenvironment.
METHODS: We analysed 44 gene expression profiles of cHL whole tumour tissues, 25 cases of NS and 19 cases of MC, using
Affymetrix chip technology and immunohistochemistry.
RESULTS: In the NS subtype, 152 genes showed a significantly higher expression, including genes involved in extracellular matrix (ECM)
remodelling and ECM deposition similar to wound healing. Among these were SPARC, CTSK and COLI. Immunohistochemistry
revealed that the NS-related genes were mainly expressed by macrophages and fibroblasts. Fifty-three genes had a higher expression
in the MC subtype, including several inflammation-related genes, such as C1Qa, C1Qb and CXCL9. In MC tissues, the C1Q subunits
were mainly expressed by infiltrating macrophages.
CONCLUSIONS AND INTERPRETATIONS: We suggest that the identified subtype-specific genes could reflect different phases of wound
healing. Our study underlines the potential function of infiltrating macrophages in shaping the cHL tumour microenvironment.
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Classical Hodgkin’s lymphoma (cHL), although a malignant
disease, has many features in common with an inflammatory
condition. cHL often presents with symptoms of fever, night
sweats, itching, lymphadenopathy and splenomegaly. Laboratory
findings include neutrophilia, eosinophilia, lymphocytopenia and
altered serum phase reactants. Classical Hodgkin’s lymphoma is
characterised by the presence of Hodgkin’s Reed–Sternberg
(H-RS) cells. The H-RS cells originate from transformed pre-
apoptotic germinal centre B-cells that have lost their capacity to
express a high-affinity B-cell receptor (Kuppers et al, 1994;
Brauninger et al, 2006). The H-RS cells constitute only a small
minority (B1%) of the cell population of the tumour. The
inflammatory cellular infiltrate in the cHL tumour tissue is
heterogeneous, consisting of lymphocytes, macrophages, eosino-
phils, mast cells, plasma cells and fibroblasts. There is evidence
that these infiltrating cells are involved in a reactive inflammatory
process creating an environment that allows and probably
promotes the survival of H-RS cells (Poppema and van den Berg,
2000; Aldinucci et al, 2002). In cHL, cytokines and chemokines
operate in a complex interaction, which seems to be important for
the pathogenesis of cHL (Re et al, 2005). Several studies indicate
that the release of biologically active mediators from H-RS cells,
such as cytokines (e.g., interleukin (IL) 13), has an important
function in the pathophysiology of cHL (Skinnider et al, 2001;
Trieu et al, 2004).
On the basis of morphology, cHL is divided into four subtypes:
nodular sclerosis (NS), mixed cellularity (MC), lymphocyte rich
and lymphocyte depleted. Ninety percent of cHL cases belong to
the MC or NS subtype. The composition of the tumour tissue
differs between the NS and MC subtypes. Nodular sclerosis
subtype is usually associated with eosinophilia and high numbers
of CD4-positive T cells. Nodular sclerosis also has a characteristic
desmoplasia and displays a distinct extracellular matrix (ECM)
deposition. Mixed cellularity is often characterised by the presence
of epithelioid macrophages. Earlier gene expression studies of
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whole-tissue cHL tumour biopsies have identified possible
prognostic markers as well as genes affected by the Epstein–Barr
Virus (EBV) (Devilard et al, 2002; Sanchez-Aguilera et al, 2006;
Baumforth et al, 2008).
The primary aim of this study was to establish the molecular
characteristics of the two major cHL subtypes, NS and MC, using
gene expression profiling and immunohistochemistry.
To visualise the cell type(s) expressing the subtype-specific
genes, the same tumours were analysed by immunohistochemistry.
Our results indicate that macrophages have an important function
in shaping the tumour microenvironment in cHL.
MATERIALS AND METHODS
Patients
Diagnostic lymph node biopsies from cHL patients were collected
from 1994 to 2004 at the Department of Pathology and Cytology,
Karolinska University Hospital Solna, Sweden (n¼ 32) and obtained
from the Children’s Cancer and Leukaemia Group (CCLG), UK
(n¼ 10). Of the Swedish samples, one NS and one MC tumour was
arrayed twice, making the number of tumour gene expression
profiles 44. The median age of all patients was 20 years (range; 6–90);
the median age of NS patients was 17 (range; 13–69), and it was 52
for MC patients (range; 6–90). The male/female ratio was 16 : 6 in the
NS group and 14 : 5 in the MC group. Of 41 of 42 tumours analysed
for EBV status, 17 were EBV-positive. These included 7 of 24 analysed
NS tumours and 10 of 18 analysed MC tumours.
This study was performed with ethics approval from the South
Birmingham Research Ethics Committee (LREC no. 0844) and
from the Karolinska Institutet Research Ethics Committee North
(approval number 01-004).
Samples
Fragments of fresh lymph node biopsies were snap-frozen in liquid
nitrogen and stored at 801C. The cHL cases were diagnosed
according to the criteria of the WHO classification (Jaffe et al,
2001). Routine morphological and immunohistochemical staining
(CD30, CD20, CD3, CD15, ALK-1), which were necessary to
establish diagnosis, were carried out on paraffin sections. EBV
expression was investigated by immunohistochemistry (latent
membrane protein 1) and in situ hybridisation (EBV encoded
RNA) as described earlier (Axdorph et al, 1999).
Morphological evaluation
A comprehensive evaluation of the morphology and infiltration by
various cell types was performed on 28 of 42 tumours by one of us
(AP). The degree of eosinophilia and the number of H-RS cells
were determined by the random selection of 10 consecutive high
power fields (HPFs) in haematoxylin–eosin-stained paraffin
sections. In each HPF, the number of eosinophils or H-RS cells
was determined and the sum for 10 HPF was calculated. The
biopsies were then classified as low eosinophilia (o50 eosinophils/
10 HPF), medium eosinophilia (50–120 eosinophils/10 HPF) or
high eosinophilia (4120 eosinophils/10 HPF). The number of
H-RS cells was detected by CD30 immunohistochemistry and
classified as few (o5 H-RS cells/10 HPFs), medium (5–10 H-RS
cells/10 HPFs) or many (410 H-RS cells/10 HPFs).
The numbers of infiltrating macrophages were evaluated on the
basis of CD68 staining and/or morphology and the tumours were
divided into two groups: with high and low macrophage counts.
The degree of fibrosis was classified into four groups based on
morphology and reticulin staining (Gordon-Sweet); 0 for no
fibrosis, 1 for slight fibrosis, 2 for advanced fibrosis, 3 for highly
advanced fibrosis (Table 1).
RNA preparation and evaluation
RNA extraction from biopsies was performed either with the
Ultraspec-II RNA isolation system (Biotecx, Houston, TX, USA)
according to the manufacturer’s protocol or with the Qiagen
RNeasy minikit (Valencia, CA, USA) with a minor modification,
that is, the amount of lysis buffer was increased to 500 ml.
Microarrays
The labelling and hybridisation were performed according to the
standard Affymetrix protocols at the KI Microarray Core Facility,
Novum, Huddinge, Sweden (http://www.bea.ki.se/affymetrix/) or
at Cancer Research UK (CRUK), Birmingham University, Birming-
ham, UK. Two different array Affymetrix designs were used: the
U133þ 2 and the human genome focus (HGF) arrays containing
8793 genes (including internal controls). The probe sets in the HGF
arrays are a subset of those present on the U133þ 2 arrays, which
makes them comparable.
Bioinformatics
We used the Affymetrix GCOS (Santa Clara, CA, USA) software to
convert the CEL files into absolute statistical signals and the
samples were scaled to the average signal of 100. The first step in
the analysis was to assess the quality reports. Our inclusion criteria
were as follows: average present call above 40% for all the genes,
background o90, background s.d. o2, scaling factor o2 and
degradation of GAPDH as measured by 30/50-end probes ratioo2.
All samples passed four out of five criteria and were thus included
in the further analysis.
The software used to analyse the gene expression patterns in NS
and MC tumours were as follows: the Gene Expression Dynamics
Table 1 Summary of the evaluation of fibrosis and number of cells
Subtype Fibrosis Eosinophilia Macrophages
Cohort
number
1 MC 0 35 Low SWE4
2 MC 1 2 High SWE7
3 MC 2 6 High SWE9
4 MC 1 10 High SWE31
5 MC 2 19 Low SWE32
6 MC 0 15 Low SWE33
7 MC 0 5 High SWE34
8 MC 2 5 High SWE35
9 MC 1 31 High SWE37
10 MC 2 3 High SWE38
11 MC 1 26 High SWE41
12 MC 1 74 Low SWE42
13 MC 0 14 High SWE43
14 MC 0 5 High SWE50
15 NS 2 154 Low SWE44
16 NS 3 108 Low SWE45
17 NS 1 40 High SWE46
18 NS 3 142 High SWE47
19 NS 2 30 High SWE48
20 NS 2 15 Low SWE49
21 NS 1 27 High SWE51
22 NS 3 39 Low SWE52
23 NS 2 73 High SWE53
24 NS 1 90 High SWE55
25 NS 2 214 Low SWE56
26 NS 3 161 Low SWE58
27 NS 1 4 High SWE59
28 NS 2 25 High SWE60
Abbreviations: MC¼mixed cellularity; NS¼ nodular sclerosis.
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Inspector (GEDI), the Significant Analysis of Microarrays (SAM,
http://www-stat.stanford.edu/~tibs/SAM/) and the dChip software
(www.dChip.org). GEDI is a Matlab freeware program that uses
self-organising maps (SOMs) to translate high-dimensional data
into a 2D mosaic (http://www.childrenshospital.org/research/
ingber/GEDI/GEDIhome.htm).
The Gene Expression Dynamics Inspector is population-based
rather than gene-based, and is thus fit to analyse large amounts of
data. Each tile of the mosaic represents an individual SOM cluster
and is colour-coded to represent over- and under-expression of the
genes in a cluster, thus identifying the underlying gene pattern
(Eichler et al, 2003).
The CEL files were converted and normalised using the robust
multichip average method and quintile normalisation before
further analysis (Irizarry et al, 2003). The SAM software was used
for the identification of differentially expressed genes (using 1.7 as
a fold change cutoff, and 5% false discovery rate) (Tusher et al,
2001). We used SAM to investigate the correlation between gene
expression and fibrosis or eosinophilia (for 28 of the samples), and
dChip 1.3 was used for cluster analysis.
Fisher’s exact test was applied for statistical analysis of the
correlation between morphological/immunohistochemical studies
and gene expression analysis.
Real-time–PCR
For selected genes, the real-time quantitative (RT)–PCR was
performed to validate the microarray results. The same RNA
samples from 22 of the tumours were used as templates for c-DNA
reaction in the Reverse Transcription System (Promega, Madison,
WI, USA).
Taqman gene expression assays (Applied Biosystems, Foster
City, CA, USA) were used with pre-made primers and FAM-MGB
probes for secreted protein acidic and rich in cysteins (SPARC)
(Hs00234160), CCL22 (Hs0017080), CXCL9 (Hs0017065), CCL17
(Hs0017074) and C1QB (Hs00608019). Two different types of
controls were included: b-actin was used as an internal control and
EBV Namalwa DNA was used as a standard (Enbom et al, 2001).
Validation of microarray results using
immunohistochemistry
Immunohistochemistry was performed as described earlier using
Dako’s Envision kit (K5007, Dako, Glostrup, Denmark) (Reynolds
et al, 2002). The following antibodies were used: SPARC (AON-
5031, Haematologic Technologies Inc., Essex, Vermont, USA),
osteoblast-specific factor 2 (OSF2) (ab14041, Abcam, Cambridge,
UK), C1Q (A0136, Dako), CXCL9 (AF392, R&D Systems Inc.,
Abingdon, UK), AIM (3805, ProSci Inc., Poway, CA, USA) and
cathepsin K (CTSK) (ab37259, Abcam).
Dilutions used in the experiments were as follows: SPARC
1 : 100, OSF2 1 : 100, C1Q 1 : 200, AIM 1 : 100 and CTSK 1 : 50.
Of the 44 tumours analysed earlier by microarrays, paraffin
blocks from 28 samples were available for immunohistochemical
analysis.
The results were scored without knowledge of the gene
expression results and the samples were arbitrarily divided into
groups according to the level of protein expression and/or the
patterns of distribution of positive cells (Table 2).
RESULTS
Gene expression profiling discriminated between cHL
subtypes
Gene expression profiles of 25 NS and 19 MC cHL samples were
visualised and compared using the GEDI software (Figure 1). Gene
Expression Dynamics Inspector allows the comparison of profiles
based on the direct visual detection of transcriptome patterns.
Such intuitive ‘gestalt’ perception promotes the visualisation
and discovery of interesting relationships. Figure 1B and C
show that gene expression differs between the NS and MC
subtypes of cHL. Figure 1D shows a cluster of active genes specific
to NS tumours. When overlapping the MC and NS GEDI maps,
no distinctive pattern could be seen besides the lack of NS
‘specific’ genes in MC samples (Figure 1E). Thus, the MC
gene expression profile seems to be partly defined by the low
expression of NS ‘specific’ genes. Alternatively, the gene expression
patterns in MC cases might be more heterogeneous (i.e., the
variation within the MC group of samples is higher than within
the NS group).
The SAM software was used for the identification of differen-
tially expressed genes (using 1.7 as a fold change cutoff, and
5% false discovery rate). Significant Analysis of Microarrays
revealed that 152 genes had a higher relative expression in the
NS cHL, whereas 53 genes had a higher expression in the MC
samples. The high number of NS-related genes and the finding
that MC is characterised by the lack of these genes fit well with
the abovementioned results of the GEDI analysis. Selected
differentially expressed genes are given in Table 3 and the list of
all genes that differed is provided in Supplementary Table 1. It
should be mentioned that genes coding for ECM and for proteins
involved in ECM remodelling: collagen 1 (COLI), collagen III
(COLIII), lumican (LUM), laminin-b1 (LAMB1), metallomatrix-
proteinase 2 (MMP2), CTSK, connective tissue growth factor
(CTGF), SPARC and OSF2 were characteristic for the NS cHL
(Table 3). Moreover, some genes involved in inflammation,
including CCL17, CCL22 and interleukin 9 (IL9) showed higher
expression in NS samples. Several of these genes are associated
with late inflammatory responses in wound healing. The genes
characteristic for MC samples included inflammatory molecules:
C1q subunits C1Qa and C1Qb, CXCL9, CD5L, erythropoietin
receptor and apolipoprotein C1. Other MC-related genes are
known to be associated with cytotoxic T cells: CD8, GRZA and
GRZK. Cluster analysis clearly showed a division between the two
subgroups (Figure 2A).
The expression levels of five genes (SPARC, CCL17, CCL22,
CXCL9 and C1Qb) were validated using real-time–PCR (RT–
PCR), which showed a good correlation with the microarray
expression values (Table 4).
Table 2 Immunohistochemical patterns of studied gene product
expression
OSF2
Group I Low staining
Group II Strong positive staining in fibrotic bands and fibroblasts
SPARC
Group I Low number of macrophages positive
Group II High staining in macrophages and fibroblasts
CTSK
Group I Low staining
Group II High staining in macrophages and fibroblasts
Group II Extensively high staining in macrophages, fibroblasts and lymphocytes
C1Q
Group I Positive in lymphocytes, low in macrophages
Group II Positive in lymphocytes and up to 50% of macrophages
Group III Positive in lymphocytes and 50–100% or macrophages
CXCL9
Group I No/low number of cells
Group II Positive in lymphocytes
Group III Positive in macrophages and lymphocytes
Molecular profile of Hodgkin’s lymphoma infiltrate
A Birgersdotter et al
1395
British Journal of Cancer (2009) 101(8), 1393 – 1401& 2009 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
Comparison of gene expression, cellular infiltrate and
degree of fibrosis
Twenty-eight of the tumours were further examined to establish
the relationship between various gene expression patterns, the
frequency of different infiltrating cell types and the degree of
fibrosis (Table 1). Each histopathological variable was correlated
with gene expression separately for each of the two subtypes. It has
been reported earlier that eosinophilia and fibrosis are associated
with the NS subtype, so we wanted to analyse whether the
difference seen between MC and NS was purely due to a difference
in fibrosis or a difference in tissue eosinophilia. Indeed, fibrosis
was weakly associated and eosinophilia was associated with NS in
our material (Fisher’s exact test, P-value 0.057 and 0.054,
respectively). There was no difference between the subtypes
regarding the level of macrophage infiltration.
The level of fibrosis was denoted as low (0 for no fibrosis, 1 for
slight fibrosis) or high (2 for advanced fibrosis and 3 for very
advanced fibrosis) (Table 1). Comparison of samples with low and
high fibrosis using the SAM software gave 144 genes with
significantly different expression. The cluster analysis (Figure 2)
showed that the NS-related genes were also associated with both
fibrosis and tissue eosinophilia. Many of these genes were ECM
related. However, the MC-related genes were not associated with
low fibrosis or low tissue eosinophilia. Only one MC-related gene,
GZMK, could be identified from the cluster analysis heat-map as
associated with no fibrosis (Figure 2B). Comparison of samples
with high and low eosinophilia (below 70 and above 70/10 HPF)
using the SAM software yielded 116 differentially expressed genes.
Of the 32 genes that were associated with low tissue eosinophilia,
five did overlap with the MC-related genes: IRF3, GZMK, PRF1,
NKG7 and APOL3.
1106
483
139
MC vs NS overlapNS vs MC overlapMC samplesNS samplescHL average
Figure 1 Gene expression profiles of cHL tumour samples visualised by the GEDI software. Genes with similar expression levels were grouped within the
same tile; the red tiles represent highly expressed genes, yellow tiles intermediate expression and dark blue tiles represent genes with low expression. The
colour bar on the lower right shows the signal intensities represented by different colours. Map (A) shows all included tumours, and maps (B) and (C) show
samples divided according to the histopathological subtype. Maps (D) and (E) visualise the NS vs MC and MC vs NS comparisons. Map (D) shows a cluster
of genes that have a higher expression in the NS subtype. However, a similar cluster is lacking in the (E) map.
Table 3 Selected genes differentially expressed in the NS and MC subtypes of cHLa
Gene symbol Description FC (NS/MC) FDR
ECM subunits
OSF2 Osteoblast-specific factor 1264 300 0
COL3A1 Collagen, type III, a1 782 520 0
COL1A1 Collagen, type I, a1 646 430 0
LUM Lumican 527 060 0
COL1A2 Collagen, type I, a2 421 190 0
LAMB1 Laminin, b1 332 030 0
ECM remodelling genes
SPARC Secreted protein, acidic, cysteine-rich (osteonectin) 294 540 0
CTGF Connective tissue growth factor 258 620 0
CTSK Cathepsin K (pycnodysostosis) 229 730 0
MMD Monocyte to macrophage differentiation-associated 175 870 2,00E-04
Inflammation-associated genes
CCL17 Chemokine (C-C motif) ligand 17 378 390 0
CCL22 Chemokine (C-C motif) ligand 22 248 330 0
Receptors
CD5L CD5 antigen-like (scavenger receptor cysteine-rich family) 197 472 0
ECGF1 Endothelial cell growth factor 1 (platelet-derived) 190 512 0
EPOR Erythropoietin receptor 188 608 0
IFNg-regulated genes
C1QB Complement component 1, q subcomponent, b-polypeptide 227 169 0
CXCL9 Chemokine (C-X-C motif) ligand 9 189 251 0
C1QA Complement component 1, q subcomponent, a-polypeptide 185 839 0
IRF6 Interferon regulatory factor 6 175 377 0
Abbreviations: cHL¼ classical Hodgkin’s lymphoma; ECM¼ extracellular matrix; FC¼ fold change; FDR¼ false discovery rate; MC¼mixed cellularity; NS¼ nodular sclerosis.
aFull list is provided in Supplementary Table 1.
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Cell-type-specific expression
To define which cell types were responsible for the high expression
of the genes discriminating between the NS and MC cHL, the
expression of five of the corresponding proteins was analysed
by immunohistochemistry on paraffin sections (Figure 3,
Tables 2 and 5).
The OSF2 (a member of the Runt-related family of transcrip-
tion factors that has a critical function during osteoblast
differentiation) gene showed a 10-fold higher mRNA expression
in the NS subtype when compared with the MC group, which
ranked it as one of the most discriminating genes. The OSF2
protein was detected in fibrotic bands and in fibroblasts dispersed
within these bands. The staining followed the fibrotic streaks of the
tumours. The tumours were divided into two groups depending on
the staining intensity (Table 2, Figure 3A and B). The number of
NS tumours with high OSF2 expression (pattern II) was
significantly higher than that of MC tumours (Table 5, Fisher’s
exact test, P&0.001).
Secreted protein acidic and rich in cysteine (SPARC), also
known as osteonectin or BM-40, is a multifunctional glycoprotein
that belongs to the matricellular group of proteins. It modulates
cellular interaction with the ECM by its binding to structural
matrix proteins, such as collagen and vitronectin, and by its
abrogation of focal adhesions, which are features contributing to a
counter-adhesive effect on cells. The SPARC antibody showed two
distinct expression patterns (Table 2, Figure 3C and D), either
showing positive staining in scattered macrophages (pattern I) or
expression in both macrophages and fibroblasts (often within the
sclerotic bands; pattern II). Occasionally, lymphocytes were
Eosinophils
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Figure 2 (A) Shows the clustering of the 205 genes that differed between the NS and the MC subtypes of cHL. Most of the genes that have a higher
expression in the NS samples tended to be associated with the extracellular matrix, whereas the genes regulated by interferon had a higher expression in the
MC samples. (B) The heat-map shows genes associated with fibrosis. The samples were divided according to the level of fibrosis: none and low vs high and
extensive (i.e., 0 and 1 vs 2 and 3). (C) The heat-map shows the comparison between samples with high eosinophilia and low eosinophilia. Several of the
genes that are associated with NS have a high expression in samples with high eosinophilia, whereas genes involved in Toll receptor signalling have a low
expression. Arrows marking CCL11 and CCL24 are also known as eotaxin 1 and 2. The number of eosinophils is also included in the third down from the
top heat-map, also marked by an arrow. The three heat-maps show that the NS-related genes were also associated with fibrosis and eosinophilia. However,
the genes associated with MC are not included among the genes associated with low fibrosis or low eosinophilia.
Table 4 Validation of microarray results using RT–PCR
Correlation coefficient Microarray FC RT–PCR FC
SPARC 0.95 2,95 3,76
CCL17 0.82 3,80 4,68
CCL22 0.63 2,48 14,96
C1q 0.61 2,27 1,8
CXCL9 0.91 1,89 5,68
Abbreviations: FC¼ fold change; RT–PCR¼ real-time–PCR.
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positive. The expression pattern II was seen more often in NS cases
(Table 5, Fisher’s exact test, P¼ 0.0047)
Cathepsin K, encoded by the CTSK gene, is a protease involved
in bone resorption. Three staining patterns were found using the
CTSK antibody (Table 2, Figure 3E, F and G). Pattern I showed low
expression in a few scattered macrophages, pattern II had a strong
expression seen mostly in macrophages and pattern III had the
highest expression, which was seen in fibroblasts, macrophages
Figure 3 Cell-type-specific expression of selected gene products revealed by immunohistochemistry. The immunohistochemistry patterns summarised in
Table 2 are illustrated. (A) Pattern I of OSF2 expression showing a positive staining around a vessel in an MC case. (B) Pattern II of OSF2 expression
showing an extensive positive staining in fibrotic streaks surrounding nodules in an NS case. (C) Pattern I of SPARC expression showing positive staining in
occasional macrophages in an MC case. (D) Pattern II of SPARC expression showing positive staining in macrophages and fibroblasts in an NS case.
(E) Pattern I of CTSK expression showing occasional positive lymphocytes in an MC case. (F) Pattern II of CTSK expression with positive staining in
macrophages and occasional lymphocytes in an MC case. (G) Pattern III of CTSK expression showing positive macrophages, occasional lymphocytes and
fibroblasts in an NS case. (H) Pattern I of C1Q expression showing positive staining in a few lymphocytes and occasional macrophages in an NS case.
(I) Pattern II of C1Q expression showing positive staining in macrophages in an NS case. (J) Pattern III of C1Q expression with many positive macrophages
in an MC case. (K) Pattern I of CXCL9 expression with very scarce positive cells as shown in an NS case. (L) Pattern II of CXCL9 expression with small
clusters of positive lymphocytes as shown in an NS case. (M) Pattern III of CXCL9 expression showing positive lymphocytes, macrophages and H-RS cells in
an MC case.
Table 5 Frequency of various immunohistochemical patterns of studied gene products in NS and MC cHL
Protein
Pattern
Protein
Pattern
Protein
Pattern
Protein
Pattern
Protein
Pattern
OSF2, N¼ 23 I II SPARC, N¼ 20 I II CTSK, N¼ 20 I II III C1Q, N¼ 28 I II III CXL9, N¼ 24 I II III
MC 15 15 0 13 9 4 13 8 5 0 17 2 3 11 14 0 4 10
NS 8 1 7 7 0 7 7 0 3 4 11 1 7 1 10 7 2 1
Abbreviations: cHL¼ classical Hodgkin’s lymphoma; MC¼mixed cellularity; NS¼ nodular sclerosis.
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and in a few lymphocytes. Pattern III was seen more often in NS
samples (Table 5, Fisher’s exact test P¼ 0.0017). In some tumours,
positive vessels and a few H-RS cells were found. There was
variation in the staining patterns in both the MC and NS groups.
In certain tumours, high numbers of positive macrophages were
evenly distributed in the tissue. In other samples, the positive
macrophages clustered around fibrotic bands or ECM deposits.
C1Q is a subcomponent of complement 1 (C1), which recognises
and binds to the heavy chain of IgG or IgM, and initiates the
classical complement pathway. The antibody against C1Q
recognised both subunits-a and -b. Macrophages and lymphocytes
were positive in most samples. There was no difference in the
lymphocyte staining between the subtypes. Three C1Q
staining patterns could be distinguished, depending on the
numbers of stained macrophages (Table 2, Figure 3H, J and K).
Vessels were also positive in a fraction of tumours. The
staining pattern III, with most stained macrophages, was
significantly more frequent in the MC group (Table 5, Fisher’s
exact test P¼ 0.0067). In some MC cases, virtually all macrophages
were stained. These samples were obtained from the oldest patients
in the study.
Chemokine (C-X-C motif) ligand 9 (CXCL9) is a small cytokine
belonging to the CXC chemokine family that is also known as
Monokine induced by g-interferon. Antibody to the CXCL9 protein
stained lymphocytes, macrophages and, in some cases, H-RS cells.
Three patterns were found: occasional positive staining in
lymphocytes (I), positive staining in lymphocytes only (II) and
positive staining in lymphocytes and macrophages (III) (Table 2,
Figure 3L, M and N). Pattern III was found mainly in the MC group
(Table 5, Fisher’s exact test P¼ 0.0003).
We also stained for the CD5L/AIM protein, a soluble 38–40 kDa
glycoprotein, also known as Spa, which was expressed by
macrophages and eosinophils. The number of positive cells did
not vary according to cHL subtype (data not shown).
In Figure 4, the correlation between the gene expression signals
and the immunohistochemistry results is illustrated. The aim was
to identify which cells expressed proteins coded by identified
genes. Therefore, the division in various patterns was based not
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Figure 4 Validation of the microarray results using immunohistochemistry. The tumours were divided according to the staining patterns illustrated in
Table 2 and Figure 3. The y axis shows the gene expression signal and the x axis shows the immunohistochemistry results. NS tumours are denoted by a’
and the MC tumours are denoted by a m in the diagrams. (A) OSF2 staining, the tumours were divided into two groups. (B) SPARC staining, the tumours
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only on the number of cells or the strength of positive staining, but
also on which cell types were positive. In some cases, the combined
expression of two cell types might have the same expression level
as one cell type in other cases.
DISCUSSION
With our combined approach of gene expression profiling and
in situ analysis of tumour sections, we have advanced the
understanding of molecular differences that define the two major
subtypes of cHL. The difference in the gene expression profile
between NS and MC at the tissue level is dominated by an apparent
mimic of different phases of the normal wound-healing process.
These differences relate primarily to the phenotypes of the
infiltrating macrophages and fibroblasts. Our data suggest that
most macrophages in the NS subtype might display the so-called
M2 phenotype because of their ECM remodelling profile, whereas
those infiltrating MC tumours are similar to cytotoxic macro-
phages found in other types of lymphomas (Dave et al, 2004; de
Jong et al, 2009).
Many NS-related genes were associated with extracellular
deposition and some of the MC-related genes were associated
with cytotoxic T cells and IFNg signalling, also in line with earlier
publications (Teruya-Feldstein et al, 1999). Our results suggest that
these ECM depositions in part mimic the wound-healing processes.
Wound healing can be divided into three different phases: the
inflammatory phase, the proliferative phase and the remodelling
phase. The inflammatory phase is characterised by an increase of
stimulated epithelial and endothelial cells producing cytokines and
chemokines that recruit and activate neutrophils, macrophages,
T cells, B cells and eosinophils. In the subsequent proliferative
phase, macrophages are activated leading to degradation of the
contemporary ECM, myofibroblasts produce new ECM compo-
nents (especially collagen III) and endothelial cells form new blood
vessels. This is followed by a remodelling and maturation phase
when collagen fibres become more organised (collagen I replaces
collagen III), blood vessels are normalised and scar tissue is
eliminated (Weinberg, 2007). The inflammatory components of the
gene expression pattern in MC are similar to those of the
inflammatory wound-healing phase, whereas NS resembles the
proliferative/tissue remodelling phase.
More than 200 genes showed subtype-specific expression in NS
and MC cHL. Most of these genes showed a higher expression in
the NS subtype, whereas about 50 had a higher expression in the
MC cHL. Several of the NS-related genes were regulated by TGFb
and/or IL-13. For example, the high expression of COLI was
specific for NS, whereas COLIII was higher in NS than in MC. The
promoter of COLI contains a TGFb-responsive STAT6-binding site
(Buttner et al, 2004; Bhogal et al, 2005).
The differences in expression of subtype-related gene products
were seen primarily in macrophages and fibroblasts. However, the
level of macrophage infiltration was heterogeneous within both
cHL subtypes. In certain tumours, macrophages positive for NS-
related genes, such as cathepsin K, were evenly scattered
throughout the tissue, whereas in other samples they clustered
around ECM deposits. It has been postulated that fibroblasts take
over the wound-healing process in an inflammatory environment
where TGFb is predominant, leading to an excess of fibrosis
similar to that seen in the proliferative and tissue remodelling
phases of wound healing (Provenzano et al, 2005). Tissue growth
factor-b is also associated with the polarisation of macrophages
into the so-called M2 phenotype associated with tissue-remodel-
ling activities (Mantovani et al, 2002; Sica et al, 2008).
Our results suggest that the NS-related macrophage activity of
ECM remodelling is not present in the MC subtype of cHL. This is
supported by the increased STAT1 phosphorylation, CXCL9
expression and the expression of C1Q subunits, which are all
controlled by IFNg, a cytokine that has earlier been reported to be
increased in the MC subtype (Teruya-Feldstein et al, 1999). It has
earlier been shown that STAT1 activation in macrophages is linked
to prognosis in cHL (Sanchez-Aguilera et al, 2006). The level of
TAMs has been indicated to have poor prognostic impact on a
number of cancers, including breast cancer and follicular
lymphomas (Leek et al, 1996; Dave et al, 2004; Shunyakov et al,
2004; Sanchez-Aguilera et al, 2006). In a mouse model, it was
shown that STAT1 is activated and that the CXCL9 and
C1Q subunits are expressed in TAMs (Biswas et al, 2006). The
C1Q subunits are membrane-bound molecules that are associated
with increased phagocytic activity in macrophages (Porta et al,
2007).
The H-RS cells are thought to orchestrate the composition of the
tumour tissue by secreting inflammatory proteins and cytokines
and thereby controlling the infiltration of reactive cells. The
infiltration of non-malignant cells such as eosinophils and mast
cells has been reported to predict the outcome in cHL (Axdorph
et al, 2001; Molin et al, 2002). Various reactive cells could
contribute to malignancies such as cHL by releasing extracellular
proteases, proangiogenic factors and chemokines (Coussens and
Werb, 2002; Chiu et al, 2007). In view of the lack of an animal or in
vitro model system for cHL, it is difficult to study whether the
microenvironment affects the H-RS cells or vice versa. One could
hypothesise that the malignant H-RS cell is responsible for the
morphological differences characteristic of the subtypes, and thus
the expression of factors produced by the H-RS cells should differ
between the subtypes. Some minor subtype-specific differences in
the profiles of the H-RS cells have been reported. Phosphorylated
STAT6 is more commonly found in the H-RS cells of the NS
subtype compared with the MC cHL (Skinnider et al, 2002).
Expression of certain kinases vary between the H-RS cells in the
two subtypes depending on the EBV status (Renne et al, 2007).
However, the gene expression profiles of the H-RS cells isolated by
laser capture showed no significant differences related to cHL
subtype or EBV status (Karube et al, 2006).
Taken together, inflammatory or wound healing-related pro-
grammes, where fibroblasts and macrophages have a dominant
function, seem to distinguish between the NS and MC cHL
subtypes.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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